An environmental risk assessment (ERA) is the process of evaluating the effects of drugs for human use on the environment. ERAs must accompany all new drug market authorisations in Europe. In this article, we discuss the current guidelines on ERAs for drugs without genetically modified organisms for human use. We also discuss the role of medical writers/communicators and aspects of the guideline that may be improved upon.